

Amendments to the Claims

Claim 1 (currently amended): An isolated nucleic acid molecule comprising a nucleotide sequence:

- (a) as set forth in either SEQ ID NO: 1 or SEQ ID NO: 3;
- (b) of the DNA insert in ATCC Deposit Nos. PTA-2665 or PTA-2666;
- (c) encoding the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4;
- (d) that hybridizes to the complement of the nucleotide sequence of any of (a) - (c) under hybridization conditions of either 0.015 M sodium chloride, 0.0015 M sodium citrate at 65°C or 0.015 M sodium chloride, 0.0015 M sodium citrate, and 50% formamide at 42°C ~~allowing no more than a 21% mismatch between the nucleotide sequences~~; or
- (e) that is complementary to the nucleotide sequence of any of (a) - (c).

Claims 2 and 3 (cancelled).

Claim 4 (previously presented): A vector comprising the nucleic acid molecule of Claim 1.

Claim 5 (currently amended): A isolated host cell comprising the vector of Claim 4.

Claim 6 (currently amended): The isolated host cell of Claim 5 that is a eukaryotic cell.

Claim 7 (currently amended): The isolated host cell of Claim 5 that is a prokaryotic cell.

Claim 8 (previously presented): A process of producing a polypeptide encoded by the nucleic acid molecule of Claim 1, comprising culturing the host cell of Claim 5 under suitable conditions to express the polypeptide, and optionally isolating the polypeptide from the culture.

Claim 9 (cancelled).

Claim 10 (original): The process of Claim 8, wherein the nucleic acid molecule comprises promoter DNA other than the promoter DNA for the native TGF- β -R polypeptide operatively linked to the DNA encoding the TGF- β -R polypeptide.

Claims 11-42 (cancelled).

Claim 43 (previously presented): A composition comprising a nucleic acid molecule of Claim 1 and a pharmaceutically acceptable formulation agent.

Claim 44 (original): The composition of Claim 43, wherein said nucleic acid molecule is contained in a viral vector.

Claim 45 (previously presented): A viral vector comprising a nucleic acid molecule of Claim 1.

Claims 46-49 (cancelled).

Claim 50 (currently amended): A device, comprising:

- (a) a membrane suitable for implantation; and
- (b) cells encapsulated within said membrane, wherein said cells secrete a protein that is encoded by a nucleic acid molecule comprising a nucleotide sequence:
 - (i) as set forth in either SEQ ID NO: 1 or SEQ ID NO: 3;
 - (ii) of the DNA insert in ATCC Deposit Nos. PTA-2665 or PTA-2666;
 - (iii) encoding the polypeptide as set forth in either SEQ ID NO: 2 or SEQ ID NO: 4; or
 - (iv) that hybridizes to the complement of the nucleotide sequence of any of (i) - (iii) under hybridization conditions of either 0.015 M sodium chloride, 0.0015 M sodium citrate at 65°C or 0.015 M sodium chloride, 0.0015 M sodium citrate, and 50% formamide at 42°C allowing no more than a 21% mismatch between the nucleotide sequences; and said membrane is permeable to said protein and impermeable to materials detrimental to said cells.

Claims 51-55 (cancelled).

Claim 56 (previously presented): A nucleic acid molecule of Claim 1 attached to a solid support.

Claim 57 (previously presented): An array of nucleic acid molecules comprising at least one nucleic acid molecule of Claim 1.